
doc.ai and UCB biopharma team up to develop breakthrough AI models to advance care
Today we’re excited to announce a new collaboration with UCB, a multinational biopharma company headquartered in Brussels, Belgium, with the launch of a digital health trial for myasthenia gravis, a neuromuscular disease that can lead to impaired speech, blurred vision, difficulty swallowing, and other symptoms.